Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Lenalidomide and Paclitaxel in Prostate Cancer

This study has been terminated.
(Slow Accrual)
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00933426
First received: July 3, 2009
Last updated: December 10, 2015
Last verified: December 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)